Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.…
Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement
Spectral Medical (TSE: EDT) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 29 employees.
The shares were at 1.030 CAD on 20 November 2026, down 28.5% over 52 weeks. Its 52-week range is 0.8600 CAD to 1.540 CAD: the price is 33.1% below the high and 19.8% above the low.
Its market capitalisation is 304.52M CAD.
Spectral Medical reports return on equity of 68.4%, an operating margin of -443.4% and revenue down 59.3% year over year.
Its debt exceeds its cash by 25.54M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 3.150 CAD is 205.8% above the current price. The next earnings report is expected on 29 March 2027.